STAAR Surgical Reports Record Q1 Sales, Returns to Profitability with 119.6% Revenue Growth

summarizeSummary

STAAR Surgical announced record first-quarter net sales of $93.5 million, a 119.6% increase year-over-year, and returned to profitability with a net income of $5.2 million, significantly exceeding preliminary guidance.

check_boxKey Events

• Record Q1 Net Sales Achieved

  STAAR Surgical reported net sales of $93.5 million for Q1 2026, marking a 119.6% increase year-over-year and the highest first-quarter sales in company history. This figure surpassed the preliminary guidance of over $90 million announced on April 8, 2026.

• Return to Profitability

  The company achieved a net income of $5.2 million ($0.10 per diluted share) in Q1 2026, a significant reversal from a net loss of $54.2 million ($1.10 per diluted share) in the prior year quarter, following a challenging fiscal year 2025.

• Strong Operational Performance

  Key operational highlights include surpassing 4 million ICLs sold globally, a return to growth in China with distributor inventory normalized, a strong launch of EVO+ ICL in China, and double-digit U.S. net sales growth, exceeding $6 million for the first time.

• Improved Gross Margins

  Gross margin increased to 73.6% in Q1 2026, up from 65.8% in the prior year quarter, driven by manufacturing efficiencies and reduced costs.

auto_awesomeAnalysis

STAAR Surgical reported a significant turnaround in its first quarter 2026 financial results, achieving record net sales and returning to profitability after a challenging fiscal year 2025. Net sales of $93.5 million represent a 119.6% increase year-over-year, exceeding the company's preliminary guidance of over $90 million. The company posted a net income of $5.2 million, a substantial improvement from a net loss of $54.2 million in the prior year quarter. This strong performance, driven by a return to growth in China and double-digit sales growth in the U.S., indicates successful operational execution and improved market conditions, particularly after addressing excess distributor inventory in China. The stock is currently trading near its 52-week high, and these results could provide further upward momentum.